EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

Nivolumab plus Chemotherapie oder Ipilimumab versus Chemotherapie bei Patient:innen mit fortgeschrittenem ösophagealem Plattenepithelkarzinom (CheckMate 648): 29-Monats-Follow-up einer randomisierten, offenen Phase-III-Studie

Ken Kato iD, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo und 10 weitere

Cancer Medicine · 2024-05 · 13 (9)

DOI: 10.1002/cam4.7235 ↗

Auf einen Blick

Bei fortgeschrittenem ESCC blieb Nivolumab plus Chemotherapie oder Ipilimumab der Chemotherapie in Bezug auf das Gesamtüberleben überlegen. Für die Chemotherapie-Kombination zeigte sich auch ein PFS-Vorteil bei PD-L1 ≥1 %.

Fragestellung

Verbessern Nivolumab plus Chemotherapie oder Nivolumab plus Ipilimumab das Überleben gegenüber Chemotherapie bei zuvor unbehandeltem, fortgeschrittenem ESCC?

Methode

Offene Phase-III-Studie; 1:1:1-Randomisierung zu Nivolumab plus Chemotherapie, Nivolumab plus Ipilimumab oder Chemotherapie; 29 Monate Mindest-Follow-up.

Ergebnisse

970 Patient:innen randomisiert. OS: HR 0,59 (95 %-KI 0,46–0,76) bzw. 0,78 (95 %-KI 0,65–0,93) für Nivolumab plus Chemotherapie vs. Chemotherapie; HR 0,62 (95 %-KI 0,48–0,80) bzw. 0,77 (95 %-KI 0,65–0,92) für Nivolumab plus Ipilimumab. PFS bei PD-L1 ≥1 %: HR 0,67 (95 %-KI 0,51–0,89); HR 1,04 (95 %-KI 0,79–1,36).

Schlussfolgerung der Autor:innen

Nivolumab plus Chemotherapie und Nivolumab plus Ipilimumab zeigten weiterhin einen klinisch relevanten OS-Vorteil gegenüber Chemotherapie ohne neue Sicherheitssignale.

Kernaussagen

  • OS-Vorteil unter beiden Nivolumab-Regimen gegenüber Chemotherapie
  • PFS-Vorteil nur für Nivolumab plus Chemotherapie bei PD-L1 ≥1 %
  • Grad-3–4 therapiebedingte UAW bei 49 %, 32 % und 36 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Medicine, online erschienen am 08.05.2024. Verfasst von Ken Kato und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb in collaboration with Ono Pharmaceutical Co..

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in the CheckMate 648 trial, leading to approvals of both nivolumab‐containing regimens in many countries. We report longer‐term follow‐up data.

Methods

This open‐label, phase III trial (NCT03143153) enrolled adults with previously untreated, unresectable, advanced, recurrent, or metastatic ESCC. Patients were randomized 1:1:1 to nivolumab plus chemotherapy, nivolumab plus ipilimumab, or chemotherapy. Primary endpoints were OS and progression‐free survival (PFS) by blinded independent central review. Hierarchical testing was performed first in patients with tumor cell programmed death ligand 1 (PD‐L1) expression of ≥1% and then in the overall population.

Results

A total of 970 patients were randomly assigned. After 29 months of minimum follow‐up, nivolumab plus chemotherapy continued to demonstrate improvement in OS versus chemotherapy (hazard ratio [HR] = 0.59 [95% CI: 0.46–0.76]) in patients with tumor cell PD‐L1 expression of ≥1% and in the overall population (HR = 0.78 [95% CI: 0.65–0.93]) and with nivolumab plus ipilimumab versus chemotherapy (HR = 0.62 [95% CI: 0.48–0.80]) in patients with tumor cell PD‐L1 expression of ≥1% and in the overall population (HR = 0.77 [95% CI: 0.65–0.92]). In patients with tumor cell PD‐L1 expression of ≥1%, nivolumab plus chemotherapy demonstrated PFS benefit versus chemotherapy (HR = 0.67 [95% CI: 0.51–0.89]); PFS benefit was not observed with nivolumab plus ipilimumab versus chemotherapy (HR = 1.04 [95% CI: 0.79–1.36]). Among all treated patients ( n = 936), Grade 3–4 treatment‐related adverse events were reported in 151 (49%, nivolumab plus chemotherapy), 105 (32%, nivolumab plus ipilimumab), and 110 (36%, chemotherapy) patients.

Conclusions

Nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful OS benefit versus chemotherapy with no new safety signals identified with longer follow‐up, further supporting use as first‐line standard treatment options for patients with advanced ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabNivolumabEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansMaleFemaleMiddle AgedAgedFollow-Up StudiesAdultProgression-Free SurvivalB7-H1 AntigenAged, 80 and over

Stichwörter der Autor:innen

cancer managementcheck point controlchemotherapyclinical cancer researchclinical trialsesophageal squamous cell carcinoma

Substanzen

IpilimumabNivolumabB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Osaka University Graduate School of Medicine, Osaka, Japan.
  • Royal Marsden Hospital, London & Surrey, UK.
  • Department of Gastrointestinal Oncology, The Fifth Medical Center of the PLA General Hospital, Beijing, China.
  • Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland.
  • Akita University Hospital, Akita, Japan.

ORCID-Profile: Ken Kato, Jaffer Ajani

Förderung

  • Bristol Myers Squibb in collaboration with Ono Pharmaceutical Co.

Zitieren

APA

Kato, K., Doki, Y., Chau, I., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C. H., Adenis, A., El Hajbi, F., Di Bartolomeo, M., Braghiroli, M. I., Holtved, E., Makino, T., Blum Murphy, M., Amaya-Chanaga, C., Patel, A., Hu, N., …, & Ajani, J. (2024). Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial. Cancer Medicine, 13(9). https://doi.org/10.1002/cam4.7235

Vancouver

Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial. Cancer Medicine. 2024;13(9). doi:10.1002/cam4.7235

BibTeX
@article{Kato2024,
  author = {Kato, Ken and Doki, Yuichiro and Chau, Ian and Xu, Jianming and Wyrwicz, Lucjan and Motoyama, Satoru and Ogata, Takashi and Kawakami, Hisato and Hsu, Chih-Hung and Adenis, Antoine and El Hajbi, Farid and Di Bartolomeo, Maria and Braghiroli, Maria Ignez and Holtved, Eva and Makino, Tomoki and Blum Murphy, Mariela and Amaya-Chanaga, Carlos and Patel, Apurva and Hu, Nan and Matsumura, Yasuhiro and Kitagawa, Yuko and Ajani, Jaffer},
  title = {Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {9},
  doi = {10.1002/cam4.7235}
}
Kostenlos starten →